ConductScience.org, home

Comparison · NCT01004029-b5bc6473

17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 32 Weeks Gestation

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 32 Weeks Gestation. Trial comparisons, record NCT01004029-b5bc6473. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01004029-b5bc6473

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04780.03680.0618wilson
Risk in group 20.05190.03660.0731wilson
Risk difference, group 1 minus group 2-0.00412-0.0280.0167newcombe hybrid score
Risk ratio, group 1 over group 20.9210.5961.42log
Odds ratio, group 1 over group 20.9170.581.45log
Number needed to treat, for one fewer participant with the outcome on 17P (Hydroxyprogesterone Caproate Injection) than on Vehicle243from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 117P (Hydroxyprogesterone Caproate Injection)HPC 250 mg/mL in oil~Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.541,130OG001
Group 2VehicleCastor Oil~Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.30578OG000

Outcome

Type
SECONDARY
Title
Preterm Birth Prior to 32 Weeks Gestation
Description
Time frame
Up to 32 weeks
Population
Intent to Treat (ITT) Population - all randomized subjects regardless of whether they received study medication.

Source ClinicalTrials.gov

Trial

Title
Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
NCT number
NCT01004029
Phases
PHASE3
Conditions
Preterm Birth
Interventions
Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL, Vehicle
Lead sponsor
AMAG Pharmaceuticals, Inc.
Results first posted
2021-01-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01004029-b5bc6473